At week @ , patients receiving fesoterodine @ mg ( @ patients ) had significantly greater reductions from baseline in UUI episodes , micturitions , and urgency episodes than patients receiving fesoterodine @ mg ( @ ) or placebo ( @ ) ; diary-dry rate was significantly higher in the fesoterodine @-mg group vs the fesoterodine @-mg and placebo groups ( all P < @ ) .